REGENXBIO

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to Decline

ROCKVILLE, Md. , Aug. 1, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m.

REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational Highlights

RGNX is proceeding towards becoming a pillar of the gene therapy space for ocular diseases. However, it will need time to get there.

Regenxbio: Patience And Regular Homework Are Keys

85 subjects dosed across five cohorts in AAVIATE ®  trial evaluating RGX-314 for the treatment of wet AMD using suprachoroidal delivery Company expects to report additional suprachoroidal data later this year ROCKVILLE, Md. , July 8, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it has completed enrollment in Cohort 5 of the Phase II AAVIATE® trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) using in-office suprachoroidal delivery.

REGENXBIO Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial

In-house facility to produce NAV Technology-based AAV gene therapies at 2,000 liters scale $65 million invested in new facility, enabling end-to-end control of gene therapy manufacturing in Montgomery County, Maryland ROCKVILLE, Md. , June 9, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today is celebrating the opening of its new Manufacturing Innovation Center gene therapy manufacturing facility.

REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility

ROCKVILLE, Md. , June 7, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Jennifer Zachary to its Board of Directors, effective June 3, 2022.

Jennifer Zachary Joins REGENXBIO Board of Directors

American Axle & Manufacturing Hlds

Community Health Systems

Triumph Group

LendingTree

The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than large-cap stocks.

5 Small-Cap S&P Stocks To Buy With The Most Upside

REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - President and CEO Steve Pakola - Chief Medical Officer Vit Vasista - CFO Conference Call Participants Andreas Argyrides - Wedbush Securities Operator Good day and thank you for standing by. Welcome to the Q1 2022 REGENXBIO Inc. Earnings Conference Call.

REGENXBIO Inc. (RGNX) CEO Ken Mills on Q1 2022 Results - Earnings Call Transcript

ROCKVILLE, Md. , May 4, 2022 /PRNewswire/ -- Continues to advance RGX-314 program for the treatment of wet AMD and diabetic retinopathy; remains on track for first BLA filing in 2024 Enrollment ongoing in the pivotal ATMOSPHERE™ and ASCENT™ clinical trials of RGX-314 for the treatment of wet AMD using subretinal delivery Enrollment ongoing in AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery Enrollment complete in ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy using suprachoroidal delivery Today announced update on initiation of AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of Duchenne Continues plans for expanded enrollment of RGX-121 and RGX-111 clinical trials for the treatment of MPS II and MPS I, respectively In-house cGMP manufacturing facility is operational, allowing for high-yield manufacturing of AAV Therapeutics up to 2,000L scale $765 million in cash, cash equivalents and marketable securities as of March 31, 2022; operational runway into 2025 Conference call Wednesday, May 4 th at 4:30 p.m.

REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , May 3, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking place virtually and in Washington, D.C.

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

Corcept Therapeutics

Pacira Pharmaceuticals

Now is a good time to take a closer look at these stocks.

3 Small-Cap Medical Stocks With Big Momentum

ROCKVILLE, Md. , April 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m.

REGENXBIO to Host Conference Call on May 4 to Discuss First Quarter 2022 Financial Results and Recent Operational Highlights

Regenxbio holds the most powerful gene delivery platform on the planet. The company recently closed a $1.3B deal with AbbVie for the development of RGX314 for wet AMD.

Regenxbio: Is The Ultimate Catalyst Coming?

ROCKVILLE, Md. , April 20, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Tuesday, April 26, 2022 at 8:30 a.m.

REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Regenxbio (RGNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Regenxbio (RGNX) Moves to Buy: Rationale Behind the Upgrade

The consensus price target hints at a 101.7% upside potential for Regenxbio (RGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 102%: Here's is How to Trade

REGENXBIO's (RGNX) CEO Ken Mills on Q4 2021 Results - Earnings Call Transcript

Regenxbio (RGNX) delivered earnings and revenue surprises of 55.84% and 29.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Regenxbio (RGNX) Q4 Earnings and Revenues Beat Estimates

ROCKVILLE, Md., March 1, 2022 /PRNewswire/ -- Closed eye care collaboration agreement with AbbVie to develop and commercialize RGX-314 Received upfront payment of $370 million and eligible to receive up to $1.38 billion in additional development, regulatory and commercial milestones Continue to advance RGX-314 program for the treatment of wet AMD and diabetic retinopathy Two pivotal trials active for the treatment of wet AMD using subretinal delivery Today announced Cohort 4 enrollment complete in RGX-314 Phase II trial for the treatment of wet AMD using in-office suprachoroidal delivery; presented positive six-month data Presented positive six-month data from RGX-314 Phase II trial for the treatment of diabetic retinopathy using in-office suprachoroidal delivery Received IND clearance and Orphan Drug Designation for RGX-202 for the treatment of Duchenne Today announced that FDA has granted Rare Pediatric Disease Designation for RGX-202 AFFINITY DUCHENNETM Phase I/II clinical trial on-track to be initiated in the first half of 2022 Presented positive data from RGX-121 and RGX-111 clinical trials for the treatment of MPS II and MPS I $849 million current cash and cash equivalents of as of December 31, 2021; including upfront payment from closing of the AbbVie eye care collaboration agreement; operational runway into 2025 Conference call Tuesday, March 1 st at 4:30 p.m.

REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Feb. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, March 1, 2022, at 4:30 p.m.

REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Feb. 12, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from the ongoing Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery.

REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

Regenxbio Inc RGNX announced additional interim data from Cohorts 1-3 of Phase 1/2 trial of RGX-121 for patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II),  Get the Inside Access Traders Are Using to Profit More and Win Bigger. Don't Miss Out on Benzinga Pro!

RegenXBio Posts Updated Data From Hunter Syndrome Gene Therapy Trial

ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- RGX-111, a potential one-time gene therapy for MPS I, is well-tolerated across two dose levels, with no drug-related serious adverse events Biomarker and neurodevelopmental assessments indicate encouraging CNS profile in patients dosed with RGX-111 Evidence of systemic biomarker activity observed Phase I/II trial data are consistent with positive results from an RGX-111 single-patient IND Completed dosing of three patients in Cohort 2; Cohort 2 has been expanded to enroll up to 6 additional patients REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data are being presented at the 18th Annual WORLDSymposium™ from five patients in the ongoing Phase I/II trial and one patient from a single-patient Investigational New Drug (IND) application of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022

ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels Dose-dependent reductions in CSF biomarkers observed; Cohort 3 patients approach normal levels of D2S6 biomarker  Measures of neurodevelopmental function from patients in Cohorts 1 and 2 demonstrate continued developmental skill acquisition up to two years after RGX-121 administration  Evidence of systemic enzyme expression and biomarker activity continues to be observed  Cohort 3 expansion using commercial-scale cGMP material is planned to start in 1H 2022 REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from Cohorts 1-3 of the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome, are being presented at the 18th Annual WORLDSymposium™.

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

ROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 8:40 a.m.

News for REGENXBIO Stock (RGNX)